Hepion Pharmaceuticals Inc
HEPA
Get informed when a big investor buys or sells
+ FollowMarket Cap$768.49K
Close$
$0.19
214.2% upside
Current Fair Value
214.2% upsideUndervalued by 214.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $768,485.00 |
|---|---|
| Enterprise Value | $-1,834,095.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.88 |
| Beta | 1.65 |
| Outstanding Shares | 11,620,317 |
Return
| Return on Equity | -160.64% |
|---|---|
| Return on Assets | -110.25% |
| Return on Invested Capital | 53.57% |
Valuation & Multiples
| P/E Ratio | -0.26 |
|---|---|
| PEG | 0.3 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.74 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-200.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-190.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.61%▼ 33.81% |
|---|---|
| Total Invested | $1,389▼ 99.67% |
| Investors Holding | 1▼ 12.00% |
ESG Score
No data
About Hepion Pharmaceuticals Inc
13 employees
CEO: Robert Foster The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an im...